HRP20150771T1 - Spoj za inhibiciju notch signalnog puta - Google Patents
Spoj za inhibiciju notch signalnog puta Download PDFInfo
- Publication number
- HRP20150771T1 HRP20150771T1 HRP20150771TT HRP20150771T HRP20150771T1 HR P20150771 T1 HRP20150771 T1 HR P20150771T1 HR P20150771T T HRP20150771T T HR P20150771TT HR P20150771 T HRP20150771 T HR P20150771T HR P20150771 T1 HRP20150771 T1 HR P20150771T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- pharmaceutically acceptable
- hydrate
- acceptable salt
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 10
- 102000005650 Notch Receptors Human genes 0.000 title 1
- 108010070047 Notch Receptors Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims 2
- 208000036566 Erythroleukaemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000021841 acute erythroid leukemia Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Claims (7)
1. Spoj, naznačen time što je spoj strukture:
[image]
,
ili njegova farmaceutski prihvatljiva sol ili hidrat.
2. Spoj, naznačen time što je spoj strukture:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
3. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1, ili njegovu farmaceutski prihvatljivu sol ili hidrat, uz farmaceutski prihvatljivu podlogu.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je namijenjen upotrebi u terapiji.
5. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je namijenjen upotrebi u liječenju raka koji je akutna limfoblastična leukemija T-stanica, akutna limfoblastična leukemija, akutna mijelogena leukemija, kronična mijelogena leukemija, eritroleukemija, rak dojke, rak jajnika, melanom, rak pluća, rak gušterače, glioblastom, kolorektalni rak, rak glave i vrata, rak vrata maternice, rak prostate, rak jetre, karcinom pločastih stanica (usta), rak kože ili meduloblastom.
6. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol ili hidrat, naznačen time što je namijenjen upotrebi u liječenju raka koji je akutna limfoblastična leukemija T-stanica, kronična mijelogena leukemija, eritroleukemija, rak dojke, rak jajnika, melanom, rak gušterače, glioblastom ili kolorektalni rak.
7. Spoj u skladu s patentnim zahtjevom 1, koji je kristalni hidrat, naznačen time što ima karakteristični uzorak difrakcije rendgenskih zraka na prahu, uz upotrebu zračenja CuKα, sa signalom na 22,97 ± 0,2 °2θ, u kombinaciji s jednim ili više signala na 11,96 ± 0,2, 18,81 ± 0,2, 20,78 60,2 ili 21,07 ± 0,2 °2θ na temperaturi i uz relativnu vlažnost okoliša.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512016P | 2011-07-27 | 2011-07-27 | |
| US201161560486P | 2011-11-16 | 2011-11-16 | |
| PCT/US2012/047100 WO2013016081A1 (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
| EP12741192.4A EP2736920B1 (en) | 2011-07-27 | 2012-07-18 | Notch pathway signaling inhibitor compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150771T1 true HRP20150771T1 (hr) | 2015-08-28 |
Family
ID=46598983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150771TT HRP20150771T1 (hr) | 2011-07-27 | 2015-07-14 | Spoj za inhibiciju notch signalnog puta |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8569286B2 (hr) |
| EP (1) | EP2736920B1 (hr) |
| JP (1) | JP6027110B2 (hr) |
| KR (1) | KR101578309B1 (hr) |
| CN (1) | CN103732612B (hr) |
| AP (1) | AP4080A (hr) |
| AR (1) | AR087107A1 (hr) |
| AU (1) | AU2012287251B2 (hr) |
| BR (1) | BR112014001600B1 (hr) |
| CA (1) | CA2841178C (hr) |
| CL (1) | CL2014000175A1 (hr) |
| CO (1) | CO6862159A2 (hr) |
| CR (1) | CR20140036A (hr) |
| CY (1) | CY1116645T1 (hr) |
| DK (1) | DK2736920T3 (hr) |
| DO (1) | DOP2014000011A (hr) |
| EA (1) | EA023044B1 (hr) |
| EC (1) | ECSP14013179A (hr) |
| ES (1) | ES2544937T3 (hr) |
| GT (1) | GT201400012A (hr) |
| HK (1) | HK1194086A1 (hr) |
| HR (1) | HRP20150771T1 (hr) |
| HU (1) | HUE027534T2 (hr) |
| IL (1) | IL229988A (hr) |
| JO (1) | JO3148B1 (hr) |
| MA (1) | MA35611B1 (hr) |
| ME (1) | ME02171B (hr) |
| MX (1) | MX356536B (hr) |
| MY (1) | MY184303A (hr) |
| PE (1) | PE20141061A1 (hr) |
| PL (1) | PL2736920T3 (hr) |
| PT (1) | PT2736920E (hr) |
| RS (1) | RS54135B1 (hr) |
| SI (1) | SI2736920T1 (hr) |
| TW (1) | TWI568730B (hr) |
| WO (1) | WO2013016081A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350216B2 (en) | 2013-01-14 | 2019-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders |
| CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| TWI609687B (zh) * | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| JO3491B1 (ar) * | 2015-07-07 | 2020-07-05 | Audion Therapeutics | مركبات مثبطة لإشارات مسار notch |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20230042756A (ko) | 2016-03-15 | 2023-03-29 | 오리존 지노믹스 에스.에이. | 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물 |
| WO2017180385A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer |
| AU2017249078B2 (en) * | 2016-04-12 | 2022-10-20 | Eli Lilly And Company | Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer |
| MA45025A (fr) | 2016-05-20 | 2019-03-27 | Lilly Co Eli | Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1 |
| KR102512899B1 (ko) * | 2016-08-31 | 2023-03-23 | 일라이 릴리 앤드 캄파니 | 고형 종양의 치료를 위한 투약 요법 |
| EP3525796A1 (en) | 2016-10-12 | 2019-08-21 | Eli Lilly and Company | Targeted treatment of mature t-cell lymphoma |
| PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
| ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
| CN111902159A (zh) | 2017-11-01 | 2020-11-06 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体 |
| EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| JP2021523169A (ja) * | 2018-05-06 | 2021-09-02 | アヤラ ファーマシューティカルズ インコーポレイテッド | ビスフルオロアルキル−１，４−ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 |
| CA3114113A1 (en) | 2018-10-02 | 2020-04-09 | Frequency Therapeutics, Inc. | Pharmaceutical compositions and methods related to otic therapeutic agents |
| CN114340611A (zh) | 2019-04-08 | 2022-04-12 | 频率医疗公司 | 用于治疗听力损失的chir99021和丙戊酸的组合 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1171878C (zh) * | 1996-12-23 | 2004-10-20 | 伊兰药品公司 | 化合物、其用途以及含有所述化合物的药物组合物 |
| EP1089977A1 (en) | 1998-06-22 | 2001-04-11 | Elan Pharmaceuticals, Inc. | Compounds for inhibiting beta-amyloid peptide release and/or its synthesis |
| JP2002518483A (ja) * | 1998-06-22 | 2002-06-25 | エラン ファーマシューティカルズ，インコーポレイテッド | β−アミロイドペプチド放出を阻害するための化合物および／またはその合成 |
| CN100480248C (zh) | 2003-02-04 | 2009-04-22 | 弗·哈夫曼-拉罗切有限公司 | 用作γ-分泌酶抑制剂的丙二酰胺衍生物 |
| KR20070087233A (ko) | 2003-09-09 | 2007-08-27 | 에프. 호프만-라 로슈 아게 | 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체 |
| DK1673347T3 (en) | 2003-10-06 | 2015-10-12 | Hoffmann La Roche | SUBSTITUTED DIBENZO-AZEPINE AND BENZO-DIAZEPINE DERIVATIVES USED AS GAMMA SECRETASE INHIBITORS |
| CN101410378B (zh) | 2006-03-27 | 2012-12-05 | 霍夫曼-拉罗奇有限公司 | 作为γ分泌酶抑制剂的丙二酰胺衍生物 |
| MX2009007864A (es) * | 2007-02-02 | 2009-07-31 | Hoffmann La Roche | Derivados de 6-oxo-6,7-dihidro-5h-dibenzo[b,d]azepin-7-ilo. |
| BRPI0906831A2 (pt) | 2008-01-11 | 2019-09-24 | Hoffmann La Roche | uso de um inibidor de gama-secretase para tratamento de câncer |
| US8637493B2 (en) * | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
-
2012
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 CA CA2841178A patent/CA2841178C/en active Active
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en active Active
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/en active Active
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active IP Right Grant
- 2012-07-18 RS RS20150496A patent/RS54135B1/en unknown
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/en active Application Filing
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
-
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
-
2014
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
- 2014-07-22 HK HK14107480.6A patent/HK1194086A1/xx unknown
-
2015
- 2015-07-14 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150771T1 (hr) | Spoj za inhibiciju notch signalnog puta | |
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| JP2014527042A5 (hr) | ||
| HRP20231163T1 (hr) | Prolijekovi glutaminskih analoga | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| JP2014502638A5 (hr) | ||
| HRP20150952T1 (hr) | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe | |
| HRP20210319T1 (hr) | Kombinacije inhibitora fgfr i inhibitora igf1r | |
| HRP20161522T1 (hr) | Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom | |
| JOP20190090B1 (ar) | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان | |
| RU2018102080A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2017519027A5 (hr) | ||
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| HRP20160654T1 (hr) | 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA | |
| HRP20171895T1 (hr) | Hemisulfatna sol 5,10-metilen-(6r)-tetrahidrofolne kiseline | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| UA111604C2 (uk) | ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ | |
| EP1832288A4 (en) | STABLE GRANULAR PHARMACEUTICAL COMPOSITION OF SOLIFENACIN OR ITS SALT | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| EP2588106A4 (en) | DELAYED RELEASED PHARMACEUTICAL COMPOSITION WITH PRAMIPEXOL OR A PHARMACEUTICALLY ALLOWED SALT AND INCREASED STABILITY | |
| JP2015507020A5 (hr) | ||
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. |